Nitazoxanide or CD3+/CD4+ lymphocytes for recovery from severe Cryptosporidium infection after allogeneic bone marrow transplant?

Pediatric Transplantation

Volumn 11, Issue 1, 2007, Pages 113-116

  Faraci, M ^a   Cappelli, B ^a   Morreale, G ^a   Lanino, E ^a   Moroni, C ^a   Bandettini, R ^a   Terranova, M P ^a   Di Martino, D ^a   Coccia, C ^a   Castagnola, E ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Bone marrow transplantation; CD3+ CD4+ lymphocytes; Cryptosporidium; Nitazoxanide

Indexed keywords

AZITHROMYCIN; BASILIXIMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; NITAZOXANIDE; PAROMOMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE NONLYMPHOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CONTINUOUS INFUSION; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DISEASE SEVERITY; DRUG DOSE REDUCTION; FECES ANALYSIS; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER GRAFT REJECTION; MALE; MULTIPLE CYCLE TREATMENT; RECTUM BIOPSY; SCHOOL CHILD; SINGLE DRUG DOSE; WHOLE BODY RADIATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD3; ANTIPARASITIC AGENTS; BIOPSY; CD4-POSITIVE T-LYMPHOCYTES; CHILD; COLON; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; HUMANS; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; LYMPHOCYTE TRANSFUSION; MALE; STEM CELL TRANSPLANTATION; THIAZOLES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33846218219     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00622.x     Document Type: Article

References (12)

1. HUNTER PR, NICHOLS G. Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin Microbiol Rev 2002: 15: 145-154.
2. ATKINS JT, CLEARY TG. Cryptosporidiosis, Cyclospora infection, isosporiasis and microsporidiosis. In: FEIGIN RD, CHERRY JD, DEMMLER GJ, KAPLAN SL, eds. Textbook of Pediatric Infectious Diseases. Philadelphia: Saunders, 2004: pp. 2687-2707.
3. WHITE Jr AC. Cryptosporidiosis (Cryptosporidium hominis, Cryptosporidium parvum, and other species). In: MANDELL GL, BENNETT JE, DOOLIN R, eds. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone, 2005: pp. 3215-3228.
4. GENTILE G, VENDITTI M, MICOZZI A, et al. Cryptosporidioisis in patients with hematologic malignancies. Rev Infect Dis 1991: 13: 79-82.
5. BURGNER D, PIKOS N, EAGLES G, MCCARTHY A, STEVENS M. Epidemiology of Cryptosporidium parvum in symptomatic paediatric oncology patients. J. Paediatr Child Heath 1999: 35: 300-302.
6. RUSSELL T, LYNCH S, AND OTTOLINI JMG. Eradication of Cryptosporidium in a child undergoing maintenance chemotherapy for leukaemia using high dose azithromycin therapy. J Pediatr Hematol Oncol 1998: 20: 83-85.
7. SMITH HV, CORCORAN GD. New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004: 6: 557-564.
8. ROSSIGNOL JF, KABIL SH, EL-GOHARY Y, YOUNIS AM. Effect of nitazoxamide in diarrhea and enteritis caused by Cryptosporidium species. Clinic. Gastroenterol. Hepatol 2006: 4: 320-324.
9. ZULU I, KELLY P, NJOBVU L, et al. Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: A randomized-controlled trial. Aliment Pharmacol Ther 2005: 21: 757-763.
10. MAGI B, CANOCCHI V, TORDINI G, CELLESI C, BARBERI A. Cryptosporidium infection: Diagnostic techniques. Parassitol Res 2005: 18: 1-3.
11. ZARDI EM, PICARDI A, AFELTRA A. Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy 2005: 51: 193-196.
12. BAISHANBO A, GARGALA G, DUCLOS C, et al. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model. J Antimicrob Chemother 2006: 57: 353-355.